TSHR antagonist S37, identified by its CAS number 1217616-61-9, is a chemical compound that functions as an antagonist of the thyroid-stimulating hormone receptor (TSHR). This compound is primarily studied for its potential therapeutic applications in conditions related to thyroid hormone regulation, such as hyperthyroidism and certain thyroid cancers. Characteristically, TSHR antagonist S37 exhibits a specific binding affinity to the TSH receptor, inhibiting its activation by endogenous thyroid-stimulating hormone. This inhibition can lead to a decrease in thyroid hormone production, making it a valuable tool in research and potential clinical applications. The compound's structure typically includes functional groups that facilitate its interaction with the receptor, contributing to its antagonist properties. Additionally, studies on TSHR antagonist S37 may explore its pharmacokinetics, bioavailability, and safety profile, which are crucial for understanding its efficacy and potential side effects in therapeutic contexts. Overall, TSHR antagonist S37 represents a significant advancement in the field of endocrinology and pharmacology.

TSHR antagonist S37

1217616-61-9: TSHR antagonist S37, identified by its CAS number 1217616-61-9, is a chemical compound that functions as an antagonist of the thyroid-stimulating hormone receptor (TSHR). This compound is primarily studied for its potential therapeutic applications in conditions related to thyroid hormone regulation, such as hyperthyroidism and certain thyroid cancers. Characteristically, TSHR antagonist S37 exhibits a specific binding affinity to the TSH receptor, inhibiting its activation by endogenous thyroid-stimulating hormone. This inhibition can lead to a decrease in thyroid hormone production, making it a valuable tool in research and potential clinical applications. The compound's structure typically includes functional groups that facilitate its interaction with the receptor, contributing to its antagonist properties. Additionally, studies on TSHR antagonist S37 may explore its pharmacokinetics, bioavailability, and safety profile, which are crucial for understanding its efficacy and potential side effects in therapeutic contexts. Overall, TSHR antagonist S37 represents a significant advancement in the field of endocrinology and pharmacology.

TSHR antagonist S37 is a selective and competitive antagonist of the thyrotropin receptor (TSHR).

CAS 1217616-61-9

TSHR antagonist S37

TSHR antagonist S37

Ref: TM-T13216

TSHR antagonist S37

Ref: 54-BUP12650